Clinical trials: Angiocardiography
Coronary Artery Disease
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.
- Trial name
- NCT00594698
- Testing
- PB127 for injectable suspension
- Where
- 34 sites in United States
- Volunteers
- 150 people
- Sponsor
- Point Biomedical
Coronary Artery Disease, Angina Pectoris
Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.
This is a retrospective study, designed to be conducted at a single-center in the US. The study will conduct a one-time data abstraction from approximately 500 patient medical charts who received Age/Sex/Gene Expression score…
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- AACU (NCT02405754)
- Testing
- Corus CAD (ASGES)
- Where
- United States
- Volunteers
- 667 people
- Sponsor
- CardioDx
Moderate to Severe Chronic Kidney Disease
Follow-up Study to Previous CARE Trial
To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of…
- Trial name
- NCT00479024
- Testing
- iodinated contrast agent
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- Bracco Diagnostics, Inc
CIN
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac…
- Trial name
- NCT00289029
- Testing
- Iopamidol 370 mgI/mL
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bracco Diagnostics, Inc
Vascular Diseases
X-ray Dose Reduction Study for Cardiac Angiography and Intervention
ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly.
- Trial name
- NCT01684826
- Testing
- Angiographic run with new algorithm and low dose (50% dose), Angiographic run with predecessor algorithm and dose (100%)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Angiocardiography
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good…
- Trial name
- TRUST (NCT01206257)
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- China
- Volunteers
- 17,513 people
- Sponsor
- Bayer